Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (August 2023)
17 slides from Tela Bio's investor presentation, Aug 9, 2023
Slide 1: Investor Presentation August 2023
INVESTOR PRESENTATION August 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possi
Slide 3: TELA Bio, Inc.
TELA Bio, Inc. • Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence • $2.2B US market opportunity 1 – still in early stages of growth • Driving commercial adoption with targeted direct - sales approach • Recent product launches in growing markets: robotic hernia su
Slide 4: Reinforced Tissue Matrix
REINFORCED TISSUE MATRIX @TELABIO SCIENCE. VALUE. INNOVATION.
Slide 5: U.S. Hernia Surgery Market: ~$1.5 Billion Annual Opportunity
Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~60,000 ~345,000 ~665,000 ~40,000 $360M $515M $600M $40M 1 Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU 2 Management estimate. Mark
Slide 6: OviTex Portfolio: Designed for a Range of Hernia Patients and Surgical Techniques
OviTex Portfolio: Designed for a Range of Hernia Patients and Surgical Techniques • Coated resorbable synthetic meshes • Biologic meshes • Biologic meshes CONFIGURATION OviTex 2S 8 - layer device, with 2 “smooth sides” suitable for intraperitoneal placement Robot Compatible 1 : No Strength 2 : +++ V
Slide 7: Need for Alternative to Permanent Synthetic Mesh
Lawsuits against permanent synthetic meshes estimated to be assembled across the U.S. 3 of surgeons agree that use of permanent synthetic mesh puts patients at long - term risk of complications 1 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use
Slide 8: Low Recurrence All Applications with OviTex
LOW RECURRENCE ALL APPLICATIONS WITH OVITEX Ankney , Szotek et al. – 2021 4 * 54 patients Follow - up 3 - 38 months Ferzoco – 2018 3 * 31 patients Average follow up 13 months INGUINAL 0% Ankney , Szotek et al. – 2021 4 * 306 patients Follow up 1 - 36 months INGUINAL 1.6% Sawyer – 2018 1 * 25 patient
Slide 9: Favorable Results of OviTex in Ventral Hernia Repair
Parker et al. 8 Sivaraj et al. 5 Total enrolled patients 50 OviTex 50 Polypropylene 36 OviTex 51 Strattice 17 Permacol 37 Surgimend Length of follow - up 12 months 12 months 28.6 months (median) 34.6 months (median) 58.4 months (median) 37.5 months (median) mVHWG 32% grade 2 68% grade 3 a 94% grade
Slide 10: Positive 24-Month BRAVO Results in Ventral Hernia
* Kaplan - Meier survival estimate **No head - to - head clinical studies have been conducted. Due to differences in patient population, surgeons, surgical technique, and other variables, no direct comparisons of results can be made. For a comparative discussion of these studies, please see G. DeNot
Slide 11: Hernia Market Evolution
Permanent Synthetic Biologic Biosynthetic Resorbable Reinforced Tissue Matrix Sources for Sales Market Share (%): 2009 - 2013 = IMS Hospital Supply Index; 2018 - 2021 = iData Research MedSKU ; 2027 = Management Estimate Sources for Total US Market Size: 2021 - 2027 = DRG Hernia Repair Devices Report
Slide 12: @TELABIO
@TELABIO SCIENCE. VALUE. INNOVATION.
Slide 13: U.S. Plastic and Reconstructive Surgery Market: ~$700 Million Annual Opportunity
U.S. Plastic and Reconstructive Surgery Market: ~$700 Million Annual Opportunity Surgeons use products to reinforce soft tissue during various reconstructive surgeries 1 , including: ▫ Head and neck surgery ▫ Chest wall reconstruction ▫ Pelvic reconstruction ▫ Extremities reconstruction ▫ Breast rec
Slide 14: OviTex PRS: Specifically Designed for Plastic and Reconstructive Surgery
OviTex PRS: Specifically Designed for Plastic and Reconstructive Surgery An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch Product Features: ▫ Layers composed of biologic building block retain biologic
Slide 15: TELA Bio is growing each factor that contributes to sales
TELA Bio is growing each factor that contributes to sales, providing for multi - year, long - term growth 2021: 40 - 45 reps 1H22: 57 reps 2022: 61 reps 2023: 75 - 80 reps Driving Revenue Growth Rep Productivity Sales Force Size Product Portfolio GPO Access Clinical Data $ales • Playbook90 training
Slide 16: Delivering Revenue Growth and Margin Improvement
Delivering Revenue Growth and Margin Improvement Q2 2023 Performance ▫ Revenue of $14.5M grows 39% over corresponding period of 2022 ▫ 70% Gross Margin ▫ Cash and Cash Equivalents at June 30, 2023: $65.3M +13% +6% +34% +17% +58% +116% +44% +48% +40% +38% +46% +39% +45% +39% 55% 60% 65% 70% 75% 80% $
Slide 17: Clinical References
CLINICAL REFERENCES 1. Sawyer, M.A.J. New Ovine Polymer - Reinforced Bioscaffold in Hiatal Hernia Repair. Jsls J Soc Laparoendosc Surg 2018, 22, e2018.00057, doi:10.4293/jsls.2018.00057. 2. DeNoto, G. Bridged Repair of Large Ventral Hernia Defects Using an Ovine Reinforced Biologic: A Case Series. A